Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation
Open Access
- 14 March 2015
- journal article
- Published by Elsevier BV in Preventive Medicine Reports
- Vol. 2, 189-195
- https://doi.org/10.1016/j.pmedr.2015.03.004
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and ItalyEuropean Journal of Preventive Cardiology, 2011
- VareniclinePharmacoEconomics, 2010
- Evaluation of Cost-Utility of Varenicline Compared with Existing Smoking Cessation Therapies in South KoreaValue in Health, 2009
- Cost Effectiveness of Varenicline in Belgium, Compared with Bupropion, Nicotine Replacement Therapy, Brief Counselling and Unaided Smoking CessationClinical Drug Investigation, 2009
- Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trialThorax, 2008
- Análisis coste-efectividad de vareniclina (Champix®) en el tratamiento del tabaquismo en EspañaAnales de Medicina Interna, 2008
- Cost-Utility Analysis of Varenicline versus Existing Smoking Cessation Strategies using the BENESCO Simulation ModelPharmacoEconomics, 2008
- Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the NetherlandsCurrent Medical Research and Opinion, 2007
- Psychometric and Utility-Based Measures of Health Status of Asthmatic Patients with Different Disease Control LevelPharmacoEconomics, 2004
- Quality of Life and Utility in Patients with Non-Small Cell Lung CancerPharmacoEconomics, 2001